Abstract
The α7-nAChR plays critical roles in numerous organs and cells by regulating highly organ and cell typespecific functions. In this special issue different Authors have contributed to clarify the different roles played by the α7- nAChR. Post-translational processes such as receptor “underactivation” or “overactivation” are associated in the central nervous system with brain disorders including neurodegeneration, while also contributing to the regulation of nonneuronal cells and cancers derived from them. Current advances in the knowledge of α7-nAChR biology encourage the exploitation of this receptor as a therapeutic target for a variety of diseases, including Alzheimer’s, disease, Parkinson’s disease, cognitive decline, pain and cancer.
Keywords: α7-nAChR, biological activity, future perspectives, new drugs, toxins
Current Drug Targets
Title:A New “Era” for the α7-nAChR
Volume: 13 Issue: 5
Author(s): Patrizia Russo, Alessio Cardinale, Hildegard Shuller
Affiliation:
Keywords: α7-nAChR, biological activity, future perspectives, new drugs, toxins
Abstract: The α7-nAChR plays critical roles in numerous organs and cells by regulating highly organ and cell typespecific functions. In this special issue different Authors have contributed to clarify the different roles played by the α7- nAChR. Post-translational processes such as receptor “underactivation” or “overactivation” are associated in the central nervous system with brain disorders including neurodegeneration, while also contributing to the regulation of nonneuronal cells and cancers derived from them. Current advances in the knowledge of α7-nAChR biology encourage the exploitation of this receptor as a therapeutic target for a variety of diseases, including Alzheimer’s, disease, Parkinson’s disease, cognitive decline, pain and cancer.
Export Options
About this article
Cite this article as:
Patrizia Russo, Alessio Cardinale, Hildegard Shuller , A New “Era” for the α7-nAChR , Current Drug Targets 2012; 13 (5) . https://dx.doi.org/10.2174/138945012800398946
DOI https://dx.doi.org/10.2174/138945012800398946 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanostructural Hybrid Sensitizers for Photodynamic Therapy
Current Pharmaceutical Design Platelet-Rich Plasma Induces Mixed Osteogenic/Osteoclastogenic Phenotype in Osteosarcoma SaOS-2 Cells: Role of TGF-Beta
Current Pharmaceutical Biotechnology Filling the Gaps between the In Vivo and In Vitro Microenvironment: Engineering of Spheroids for Stem Cell Technology
Current Stem Cell Research & Therapy Status of Non-Classical Mononuclear Platinum Anticancer Drug Development
Mini-Reviews in Medicinal Chemistry Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Current Drug Targets Malignant Pleural Effusions: Review of Treatment and Our Experience
Reviews on Recent Clinical Trials Notch Signaling: A Potential Therapeutic Target in Prostate Cancer
Current Cancer Drug Targets Gene Therapy Approaches for the Selective Killing of Cancer Cells
Current Pharmaceutical Design Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics
Current Pharmaceutical Biotechnology Neuroprotective Effects of Melanocortins in CNS Injury
Current Pharmaceutical Design Targeting Tumor Lymphangiogenesis: An Update
Current Medicinal Chemistry Macromolecular Drug Targets in Cancer Treatment and Thiosemicarbazides as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Carbon Nanotubes – Curse or Blessing
Current Medicinal Chemistry TNF-Related Apoptosis-Inducing Ligand (TRAIL) as a Pro-Apoptotic Signal Transducer with Cancer Therapeutic Potential
Current Pharmaceutical Design Idronoxil as an Anticancer Agent: Activity and Mechanisms
Current Cancer Drug Targets Histone Deacetylase Inhibitors as Potential Therapeutic Agents for the Treatment of Malignant Mesothelioma
Anti-Cancer Agents in Medicinal Chemistry Genistein Affects Expression of Cytochrome P450 (CYP450) Genes in Hepatocellular Carcinoma (HEPG2/C3A) Cell Line
Drug Metabolism Letters Tamoxifen and its New Derivatives in Cancer Research
Recent Patents on Anti-Cancer Drug Discovery HGF Airway Over-expression Leads to Enhanced Pulmonary Vascularization without Induction of VEGF
Current Angiogenesis (Discontinued) MicroRNA: Biogenesis, Function and Role in Cancer
Current Genomics